#Canada #Vancouver #Migraine #InMed #Mentari

InMed Pharmaceuticals and Mentari Therapeutics Merger

InMed Pharmaceuticals, Inc. (NASDAQ: INM) has officially announced a merger with Mentari Therapeutics, Inc., a biotechnology firm focused on innovative therapies for preventing migraines. This strategic partnership represents a significant advancement in Migraine treatment due to Mentari’s unique drug pipeline designed to target patients who have not responded sufficiently to existing therapies.

Background of the Companies

InMed Pharmaceuticals is known for its commitment to developing pharmaceutical solutions with a focus on cannabinoid-based therapies. Meanwhile, Mentari Therapeutics specializes in targeting a newly identified pathway for migraine prevention, aimed at addressing the unmet needs of the two-thirds of patients who do not respond adequately to anti-CGRP treatments. The merger creates a foundation for the combined entity, expected to trade under the new name, Mentari Therapeutics, Inc., on the Nasdaq Capital Market.

Key Financials and Funding

The merger will be supported by a concurrent private placement targeting gross proceeds of approximately $290 million, designed to fund operational activities through 2028. This financial boost will facilitate both companies’ dedication to clinical trials and regulatory submissions for their lead products MT-001 and MT-002. Notably, MT-001 is an anti-PACAP monoclonal antibody, while MT-002 targets both CGRP and PACAP, marking them as potentially best-in-class migraine therapies.

Expected Milestones

• - MT-001 is projected to have Phase 2a proof-of-concept data by 2028.
• - MT-002's expected results from Phase 1 healthy volunteer trials are due in 2027.

Together, both drug candidates may have the potential to significantly decrease the frequency and severity of migraines, thereby improving the quality of life for millions of patients suffering from this debilitating condition.

Statements from Leadership

Eric A. Adams, President and CEO of InMed, stated, "This merger presents an incredible opportunity for InMed shareholders to engage with a promising new drug pipeline that has substantial therapeutic and commercial promise." He expressed confidence in Mentari's strong balance sheet and operational strategies.

Julie Bruno, Chair of Mentari's board, highlighted that this transaction will provide the necessary capital and framework to compete effectively in the evolving migraine treatment landscape. Brimming with optimism about their dual-targeted approach, she noted that recent anti-PACAP studies have generated substantial interest and could transform how migraine treatment is approached.

Pipeline and Development Plans

Mentari's focus on developing therapies that exert dual pathway inhibition marks a new direction in migraine management. The lead products, MT-001 and MT-002, have demonstrated promising in vitro potency. The merger aims to expedite their progress through clinical trials and eventually into the hands of patients.

Moreover, the merger will allow the consolidation of InMed’s public market framework with Mentari’s pipeline of therapeutics, promising to enhance both companies’ capabilities in delivering essential new therapies to patients.

Conference Call and Future Outlook

InMed will host a conference call on May 19, 2026, at 8:30 AM EDT to discuss the implications of the merger, providing investors with detailed insights into future plans and operational strategies. Participants can join the call via the provided toll-free numbers, ensuring a wide reach among interested stakeholders.

In conclusion, this merger not only symbolizes a strategic alliance but also brings hope to the millions of individuals grappling with chronic migraines. The focus on innovative treatment pathways and robust clinical development projects highlights both companies' commitment to transforming migraine therapies and improving patient outcomes significantly.